Pfizer says Covid-19 pill Paxlovid cuts hospitalisation and deaths by 89 per cent

Nov 5, 2021 | INVESTING

A trial of Pfizer’s experimental antiviral pill for Covid-19 was stopped early after the drug was shown to cut by 89 per cent the chances of hospitalisation or death for adults at risk of developing severe disease, the company said on Friday.The results appear to surpass those seen with Merck’s pill, molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalised for Covid-19 patients also at high risk of serious illness.Full trial data is not yet available from…

Read More

Pin It on Pinterest